Lobbying disclosures · Lobbying report
LLY: second_quarter 2026 lobbying report
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to FDA regulation of pharmaceuticals. Issues related to the 340B program. Issues related to treatments for Alzheimers therapeutics.
Follow LLY- Became public
- Jul 9, 2026, 10:22 AM EDT
- Event / period date
- Not stated
- Collected
- Nov 9, 2026, 4:19 PM EST
Why this is connected
Legal-name match: ELI LILLY AND COMPANY is ELI LILLY & Co (https://www.sec.gov/Archives/edgar/data/59478/), differing only in punctuation, "the" or suffix spelling (Corp/Corporation).
Reported lobbying amounts
Income: $60,000.00
These are different reporting measures. They are not added together or treated as spending on one particular bill.
Source evidence
Read the source excerpt or record
{"url":"https://lda.gov/api/v1/filings/457363b4-77ad-4c44-bf99-e5569816783b/","filing_uuid":"457363b4-77ad-4c44-bf99-e5569816783b","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/457363b4-77ad-4c44-bf99-e5569816783b/print/","filing_document_content_type":"text/html","income":"60000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Beth Anne Cole","dt_posted":"2026-07-09T10:22:57-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"611 2nd Street, NE","registrant_address_2":"Suite 1","registrant_different_address":true,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20002","registrant":{"id":401105121,"url":"https://lda.gov/api/v1/registrants/401105121/","house_registrant_id":44305,"name":"MARSHALL & POPP, LLC","description":"​Government affairs and consulting firm.","address_1":"611 2nd Street, NE","address_2":"Suite 1","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20002","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"BETH ANNE COLE","contact_telephone":"+1 202-321-1811","dt_updated":"2026-07-13T16:40:37.032909-04:00"},"client":{"id":65133,"url":"https://lda.gov/api/v1/clients/65133/","client_id":65133,"name":"ELI LILLY AND COMPANY","general_description":"Biopharmaceutical manufacturer.","client_government_entity":null,"client_self_select":false,"state":"IN","state_display":"Indiana","country":"US","country_display":"United States of America","ppb_state":"IN","ppb_state_display":"Indiana","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2025-03-14"},"lobbying_activities":[{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to FDA regulation of pharmaceuticals. Issues related to the 340B program.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":70852,"prefix":null,"prefix_display":null,"first_name":"HAZEN","nickname":null,"middle_name":"CLAY","last_name":"MARSHALL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70067,"prefix":null,"prefix_display":null,"first_name":"MONICA","nickname":null,"middle_name":null,"last_name":"POPP","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Issues related to treatments for Alzheimers therapeutics.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":70852,"prefix":null,"prefix_display":null,"first_name":"HAZEN","nickname":null,"middle_name":"CLAY","last_name":"MARSHALL","suffix":null,"suffix_display":null},"covered_position":"Policy Director-Senate Majority Leader Mitch McConnell; Staff Director, Senate Budget Committee-Senator Don Nickles; Deputy Chief of Staff/Economist, Office of Assistant Majority Leader-Senator Don Nickles; Legislative Assistant-Senator Don Nickles","new":false},{"lobbyist":{"id":70067,"prefix":null,"prefix_display":null,"first_name":"MONICA","nickname":null,"middle_name":null,"last_name":"POPP","suffix":null,"suffix_display":null},"covered_position":"Chief of Staff/Deputy Chief of Staff, Office of Senate Republican Whip John Cornyn; Professional Staff Member, U.S. House of Representatives-Energy & Commerce Committee; Legislative Assistant, Senator Jim DeMint","new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}Price change after we could observe it
+0.38% LLY
Adjusted closing prices from Nov 10, 2026 to Nov 11, 2026. SPY changed 1.32% over the same dates. The start is the first available close after both publication and collection. This is a price comparison, not an executed trade, investor profit, or a backtested strategy.
Congressional trading in LLY
These disclosures provide context. Their presence does not establish a link between a trader and the event.
- Nov 10, 2026$1K–$15K
Rep. Gilbert Ray Cisneros, Jr. (D-CA-31)
Bought Eli Lilly and Company LLY
$1K–$15K · Traded Oct 20, 2026 · disclosed Nov 10, 2026
Traded 9 days before earnings - Oct 7, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
Bought Eli Lilly and Company LLY
$1K–$15K · Traded Sep 4, 2026 · disclosed Oct 7, 2026 · Spouse
- Aug 7, 2026$1K–$15K
Rep. Michael A. Rulli (R-OH-6)
Sold Eli Lilly and Company LLY
$1K–$15K · Traded Jul 1, 2026 · disclosed Aug 7, 2026
Committee overlap: Energy and CommerceGot $1K from the company’s PAC - Aug 7, 2026$1K–$15K
Rep. Michael A. Rulli (R-OH-6)
Bought Eli Lilly and Company LLY
$1K–$15K · Traded Jan 2, 2026 · disclosed Aug 7, 2026 · filed 217 days later
Committee overlap: Energy and CommerceGot $1K from the company’s PAC - Aug 7, 2026$1K–$15K
Rep. Michael A. Rulli (R-OH-6)
Sold Eli Lilly and Company LLY
$1K–$15K · Traded Dec 2, 2025 · disclosed Aug 7, 2026 · filed 248 days later
Committee overlap: Energy and CommerceGot $1K from the company’s PAC - Jul 21, 2026$1K–$15K
Sen. Alan Armstrong (R-OK)
Sold (full) Eli Lilly and Company LLY
$1K–$15K · Traded Mar 27, 2026 · disclosed Jul 21, 2026 · filed 116 days later
Committee overlap: HELP - Jul 17, 2026$1K–$15K
Rep. Dan Newhouse (R-WA-4)
Sold (partial) Eli Lilly and Company LLY
$1K–$15K · Traded Jul 10, 2026 · disclosed Jul 17, 2026 · Spouse
- Jul 2, 2026$50K–$100K
Rep. Gilbert Ray Cisneros, Jr. (D-CA-31)
Bought Eli Lilly and Company LLY
$50K–$100K · Traded Jun 10, 2026 · disclosed Jul 2, 2026
Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.